clonidine has been researched along with Movement Disorders in 14 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-nine patients with tardive dyskinesia (n = 20) or related syndromes [spontaneous dyskinesia (n = 3), levodopa-induced dyskinesia (n = 3), tardive dystonia (n = 3)] were treated with clonidine." | 3.67 | Clonidine therapy for tardive dyskinesia and related syndromes. ( Koga, I; Nishikawa, T; Tanaka, M; Tsuda, A; Uchida, Y, 1984) |
| "In childhood, movement disorders are generated by a very large number of disorders of the nervous system, and the very different developmental ages at which these occur make studies of pharmacotherapy efficacy extremely difficult." | 2.55 | Advances in pharmacotherapies for movement disorders in children: current limitations and future progress. ( Lin, JP, 2017) |
| "Movement disorders are subdivided based on a variety of criteria." | 2.38 | Treatment of hyperkinetic movement disorders. ( Bressman, SB; Greene, PE, 1990) |
| "Pretreatment with yohimbine (2mg/kg, i." | 1.37 | Icilin-evoked behavioral stimulation is attenuated by alpha₂-adrenoceptor activation. ( Cowan, A; Hirsch, DD; Kim, J; Lisek, R; Rawls, SM; Raymondi, N; Rosenthal, A, 2011) |
| "Cervical incomplete spinal cord injuries often lead to severe and persistent impairments of sensorimotor functions and are clinically the most frequent type of spinal cord injury." | 1.37 | Motor deficits and recovery in rats with unilateral spinal cord hemisection mimic the Brown-Sequard syndrome. ( Filli, L; Schwab, ME; Weinmann, O; Zörner, B, 2011) |
| "Treatment with clonidine significantly slowed the rate of recovery (Kruskal-Wallis H = 8." | 1.28 | Clonidine impairs recovery of beam-walking after a sensorimotor cortex lesion in the rat. ( Davis, JN; Goldstein, LB, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, JP | 2 |
| Niederhofer, H | 1 |
| Bamford, A | 1 |
| Crowe, BH | 1 |
| Hacohen, Y | 1 |
| Clarke, A | 1 |
| Tudor-Williams, G | 1 |
| Sancho-Shimizu, V | 1 |
| Vincent, A | 1 |
| Lim, M | 1 |
| Pullaperuma, SP | 1 |
| Benecke, R | 1 |
| Patejdl, R | 1 |
| Kim, J | 1 |
| Cowan, A | 1 |
| Lisek, R | 1 |
| Raymondi, N | 1 |
| Rosenthal, A | 1 |
| Hirsch, DD | 1 |
| Rawls, SM | 1 |
| Filli, L | 1 |
| Zörner, B | 1 |
| Weinmann, O | 1 |
| Schwab, ME | 1 |
| Kasim, S | 1 |
| Jinnah, HA | 1 |
| Nishikawa, T | 1 |
| Tanaka, M | 1 |
| Tsuda, A | 1 |
| Koga, I | 1 |
| Uchida, Y | 1 |
| Ringwald, E | 1 |
| Campean, SJ | 1 |
| Gerstenbrand, F | 1 |
| Lorincz, A | 1 |
| Lörincz, P | 1 |
| Ludin, HP | 1 |
| Bressman, SB | 1 |
| Greene, PE | 1 |
| Goldstein, LB | 1 |
| Davis, JN | 1 |
| Sandyk, R | 1 |
| Pranzatelli, MR | 1 |
| Schultz, L | 1 |
| Snodgrass, SR | 1 |
| Caine, ED | 1 |
| McBride, MC | 1 |
| Chiverton, P | 1 |
| Bamford, KA | 1 |
| Rediess, S | 1 |
| Shiao, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment: Double Blinded Comparison Between Botulinum Toxin and Baclofen.[NCT02462317] | Phase 4 | 184 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for clonidine and Movement Disorders
| Article | Year |
|---|---|
Advances in pharmacotherapies for movement disorders in children: current limitations and future progress.
Topics: Amines; Anti-Dyskinesia Agents; Child; Clonidine; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Ami | 2017 |
[New therapies for spastic movement disorders].
Topics: Administration, Oral; Baclofen; Botulinum Toxins, Type A; Cannabinoids; Clonidine; Diazepam; Humans; | 2009 |
Treatment of hyperkinetic movement disorders.
Topics: Benzodiazepines; Clonidine; Dystonia; Humans; Levodopa; Movement Disorders | 1990 |
The endogenous opioid system in neurological disorders of the basal ganglia.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clonidine; Endorphins; gamma-Aminobutyric Aci | 1985 |
1 trial available for clonidine and Movement Disorders
| Article | Year |
|---|---|
[Clinical experiences with a new muscle relaxant (DS 103-282 Sandoz) (author's transl)].
Topics: Adult; Clinical Trials as Topic; Clonidine; Drug Evaluation; Drug Tolerance; Female; Humans; Male; M | 1977 |
9 other studies available for clonidine and Movement Disorders
| Article | Year |
|---|---|
Tizanidine is not effective treating EPMS.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Biperiden; Cholinergic Antagonists; Clonidine; Clopenthix | 2018 |
Pediatric Herpes Simplex Virus Encephalitis Complicated by N-Methyl-D-aspartate Receptor Antibody Encephalitis.
Topics: Acyclovir; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiviral Agents; Autoantibodies; Clonid | 2015 |
Icilin-evoked behavioral stimulation is attenuated by alpha₂-adrenoceptor activation.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Agmatine; Analysis of | 2011 |
Motor deficits and recovery in rats with unilateral spinal cord hemisection mimic the Brown-Sequard syndrome.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Apomorphine; Brown-Sequard Syndrome; Clonidine; Dis | 2011 |
Pharmacologic thresholds for self-injurious behavior in a genetic mouse model of Lesch-Nyhan disease.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2002 |
Clonidine therapy for tardive dyskinesia and related syndromes.
Topics: Adult; Aged; Clonidine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle A | 1984 |
Clonidine impairs recovery of beam-walking after a sensorimotor cortex lesion in the rat.
Topics: Animals; Brain Injuries; Cerebral Cortex; Cerebrovascular Disorders; Clonidine; Disease Models, Anim | 1990 |
High-dose clonidine motor syndrome: relationship to serotonin syndrome.
Topics: Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Brain; Clonidine; Dose-Response Relationshi | 1987 |
Tourette's syndrome in Monroe County school children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Child, Preschool; Clonid | 1988 |